Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market to 2032

Overview

The Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market is expected to reach a 413.34 USD Billion by 2032 and is projected to grow at a CAGR of 17.18% from 2025 to 2032.

Revenue, 2024 (USD Billion)

180.73

Forecast, 2032 (USD Billion)

413.34

CAGR, 2024 - 2032

17.18%

Report Coverage

Asia-Pacific

Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market 2018-2032 USD Billion

Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market, Key Findings (2025-2032)

Market Growth and Projections:

Market Size (2024): 180.73 USD Billion
Projected Market Size (2032): 413.34 USD Billion
CAGR (2025-2032): 17.18%

Key Findings of Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market

The Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market was valued at 180.73 USD Billion in 2024.
The Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market is likely to grow at a CAGR of 17.18% during the forecast period of 2024 to 2032.
In 2024, the Largest segment Saliva in Sample Segment accounted for the largest share of the market with a revenue of 116.61 USD Billion
The fastest growing segment CYP2C19 in Genes Segment grew Fastest with a CAGR of 22.76% during the forecast period from 2024 to 2032.

Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market Scope

Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market Segmentation & Scope

Sample

Blood
Saliva

Drug Type

Vitamins/Nutraceuticals
Recreational Drugs
Over-The-Counter Medications
Prescription Drugs

Genes

COMT
MTHFR
SLC6A4
CYP3A4
HLA-A
HTR2A/C
Others
HLA-B
CYP2D6
CYP2C9 AND VKORC1
CYP2C19

Application

Clinical Practice
Drug Development

Type

Array-Based Tests
Whole Genome Sequencing

End User

Others
Research Centres And Academic Institutes
Healthcare Providers
Pharmaceutical & Biotechnology Companies

Distribution Channel

Direct-To-Customer Services
Mail-Order Pharmacies
Hospital Pharmacies
Retail Pharmacies

Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market Data Coverage Insights

Study Period	2024-2032
Base Year	2020
Unit	Revenue in USD Billion
Market Value in 2024	180.73 USD Billion
Market Value in 2032	413.34 USD Billion
CAGR (2025-2032)	17.18%
Historic Data	2016-2023
Market Segments Covered	Sample,Drug Type,Genes,Application,Type,End User,Distribution Channel

Regional Insights:

Leading Market (2024-2032): Asia-Pacific, leading in terms of revenue 180.73 USD Billion in 2024
- Key Country: Japan, leading in terms of revenue with value of 41.76 USD Billion in 2024.

Segments and Scope

Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Sample
- Saliva is the largest segment in Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 116.61 USD Billion in the year 2024.
- Saliva is the Fastest growing segment in Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 17.85 % in forecast period 2025-2032.
Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Drug Type
- Prescription Drugs is the largest segment in Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 83.01 USD Billion in the year 2024.
- Recreational Drugs is the Fastest growing segment in Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 17.60 % in forecast period 2025-2032.
Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Genes
- CYP2C19 is the largest segment in Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 42.93 USD Billion in the year 2024.
- CYP2C19 is the Fastest growing segment in Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 22.76 % in forecast period 2025-2032.
Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Application
- Drug Development is the largest segment in Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 101.61 USD Billion in the year 2024.
- Drug Development is the Fastest growing segment in Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 17.76 % in forecast period 2025-2032.
Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Type
- Whole Genome Sequencing is the largest segment in Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 113.75 USD Billion in the year 2024.
- Whole Genome Sequencing is the Fastest growing segment in Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 17.70 % in forecast period 2025-2032.
Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market to 2032, By End User
- Pharmaceutical & Biotechnology Companies is the largest segment in Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 74.04 USD Billion in the year 2024.
- Pharmaceutical & Biotechnology Companies is the Fastest growing segment in Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 18.40 % in forecast period 2025-2032.
Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Distribution Channel
- Retail Pharmacies is the largest segment in Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 77.12 USD Billion in the year 2024.
- Hospital Pharmacies is the Fastest growing segment in Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 17.50 % in forecast period 2025-2032.

Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market Company Share Analysis

Company Name
Millennium Health
Myriad Genetics, Inc.
PerkinElmer Inc.
Illumina, Inc.
Thermo Fisher Scientific Inc.

Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market Geographical Sales Distribution, 2018-2032 USD Billion

Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market Company Profiling

Industry Related Reports

South America Cell And Gene Therapy Thawing Equipment Market

Middle East & Africa Cell And Gene Therapy Thawing Equipment Market

North America Cell And Gene Therapy Thawing Equipment Market

Europe Cell And Gene Therapy Thawing Equipment Market

Asia-Pacific Cell And Gene Therapy Thawing Equipment Market

Argentina Cell And Gene Therapy Thawing Equipment Market

Australia Cell And Gene Therapy Thawing Equipment Market

Belgium Cell And Gene Therapy Thawing Equipment Market

Brazil Cell And Gene Therapy Thawing Equipment Market

Canada Cell And Gene Therapy Thawing Equipment Market

Frequently Asked Questions

What are the primary segments covered in the Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market?

The Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market is segmented based on Segmentation Sample,Drug Type,Genes,Application,Type,End User,Distribution Channel.

What is the current market size of the Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market?

Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market was valued at USD 180.73(Revenue in USD Billion) in 2020.

What is the expected growth rate of the Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market?

Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market is projected to grow at a CAGR of 17.18% during the forecast period of 2024 to 2032.

Which is the dominating segment in the Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market?

The Saliva segment is expected to dominate the Asia-Pacific Pharmacogenetic Testing in Psychiatry depression Market, holding a largest market share of 116.61 USD Billion in 2024